What is the current Peptide and Oligonucleotide CDMO market size?

The Peptide and Oligonucleotide CDMO market size surpassed USD 2.3 billion in 2023, propelled by rising demand for biologics and nucleic-acid-based therapeutics.

What is the future outlook for market growth?

Analysts forecast a 12% CAGR through 2030, with the future outlook driven by personalized medicine, increasing drug approvals, and outsourced manufacturing efficiencies.

What are the key drivers of the Peptide and Oligonucleotide CDMO market?

Rapid growth of GLP-1 agonists, antisense and siRNA pipelines, lower internal capacity at pharma companies, and cost-saving outsourcing strategies fuel double-digit demand.

Which challenges constrain sector expansion?

High capital requirements for GMP suites, complex solid-phase synthesis, stringent impurity limits, fragmented supply chains, and talent shortages in analytical chemistry.

Which regions lead the Peptide and Oligonucleotide CDMO landscape?

North America commands 42% share via innovation clusters; Europe follows with 31% share, led by Germany and Switzerland; Asia-Pacific, especially China and South Korea, is growing fastest.

Who are the top companies in the Peptide and Oligonucleotide CDMO market?

Leaders include Bachem, PolyPeptide Group, Cambrex, Curia, CordenPharma, ST Pharm, Avecia, and WuXi STA, collectively holding over 55% of global capacity.

Which Companies Lead the Peptide and Oligonucleotide CDMO Market in 2026?

Peptide and Oligonucleotide CDMO by Type (/> Peptide CDMO, Oligonucleotide CDMO), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $2600 million

CAGR: 12.4%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $2600 million

CAGR: 12.4%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Peptide and Oligonucleotide CDMO Market Overview

The Peptide and Oligonucleotide CDMO market—contract development and manufacturing of synthetic peptides and oligonucleotide APIs—has become a strategic pillar for accelerated rare-disease and personalized-medicine pipelines. A $4.3 B market in 2025, it is forecast to reach $9.1 B by 2033, translating to a 9.4% CAGR as Big Pharma and VC-backed biotechs outsource >70% of their oligo and peptide programs. Growth is underpinned by regulatory tailwinds (FDA qualified oligo platform, EMA PRIME), the shift to high-dose GLP-1 and RNAi therapeutics, and CDMO investments in multi-product GMP suites that compress IND-to-NDA timelines by 6–9 months.

Loading chart…

Technology migration to flow-based solid-phase synthesis and high-throughput purification is cutting cost of goods by 20–30%, while tightening USP <1503> and ICH Q14 guidelines raise compliance stakes and favor Tier-1 CDMOs. North America holds the largest share (42%) driven by clustered biotech hubs and IRA-enabled domestication incentives, yet APAC—spearheaded by Korea and China—is the fastest-expanding region (11% CAGR) on the back of aggressive capacity build-outs and 25–30% price arbitrage. Consolidation is accelerating: four of the last seven quarters saw >$2.5 B in M&A as sponsors seek end-to-end peptide/oligo platforms and dual sourcing security.

Report Overview

Report Attribute	Details
Market size value in 2025	2.60 billion
Revenue forecast in 2033	6.62 billion
Growth rate	CAGR of 12.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lonza Group Ltd.; Thermo Fisher Scientific Inc.; Merck KGaA; Catalent, Inc.; Genscript Biotech Corporation; Polypeptide Group; Bachem Holding AG; Wuxi Apptec Co., Ltd.; Ajinomoto Co., Inc.; Rentschler Biopharma SE; Corden Pharma GmbH; Senn Chemicals AG; Almac Group; Lonza Custom Manufacturing; Creative Peptides; Swiss Customized Synthesis; Syngene; Eurogentec
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Peptide and Oligonucleotide CDMO market is entering a phase of accelerated expansion as drug pipelines pivot toward precision biologics and nucleic-acid modalities. Rising clinical success of GLP-1 analogs, antisense oligos, and siRNA therapies is translating into double-digit outsourcing penetration, lifting the Peptide and Oligonucleotide CDMO market size above USD 3.2 B in 2023 and underpinning a robust growth forecast of 13–15 % CAGR through 2028. However, capacity concentration, volatile raw-material pricing, and evolving CMC guidelines are tempering the pace of value creation, forcing both sponsors and contract partners to re-calculate risk-adjusted returns.

Growth Drivers2 items

Patent cliff and payer pressure are pushing biopharma to outsource >70 % of peptide/oligo manufacturing; CDMOs with integrated solid-phase and flow-chemistry suites capture incremental COGS savings of 15–20 %, accelerating adoption.

Regulatory tailwinds such as FDA’s revised peptide impurity guidance and EMA’s oligonucleotide CMC reflection paper shorten development cycles, enabling CDMOs to convert pre-clinical programs into commercial supply agreements within 24–30 months.

Restraints2 items

Supply chain fragility: single-source suppliers control >60 % of protected amino-acid and ultra-pure phosphoramidite feedstocks; recent 40–60 % price spikes have compressed CDMO gross margins by 4–6 pp, deterring aggressive capacity bets.

Bioavailability bottlenecks (e.g., lipid excipient quotas and PEGylated-linker shortages) force costly tech transfers, eroding the speed advantage that underpins the sector’s growth forecast and delaying sponsor launch timelines by 6–9 months.

Opportunities2 items

Hybrid peptide-oligo conjugates for targeted protein degradation open green-field revenue pools; CDMOs investing in dual-purpose GMP suites can secure premium pricing (20–30 % above standard) while locking in 5- to 7-year exclusivity clauses.

Emerging APAC markets (Korea, China) offer 35–45 % cost arbitrage plus expedited IND pathways; regional CDMOs leveraging local incentives can undercut Western quotes by 15 % without sacrificing quality, expanding addressable Peptide and Oligonucleotide CDMO market size.

Challenges2 items

Capital intensity: green-field peptide/oligo facilities require USD 250–300 M and 4-year lead times; rising interest rates have lifted WACC above 11 %, making capacity expansion a high-stakes gamble if clinical attrition trends reverse.

IP leakage risk during tech transfer is prompting sponsors to split workflows across multiple vendors, inflating program management overhead by 8–10 % and complicating CDMO efforts to scale sustainably within the projected growth forecast window.

Market Segmentation

Loading chart…

API dominates Peptide and Oligonucleotide CDMO segmentation, accounting for roughly 60 % of outsourced spend because peptide APIs carry 5–10× the manufacturing cost of standard small molecules, while oligonucleotide APIs demand high-cost phosphoramidite chemistries and multi-ton GMP-grade solvents. The segment is further split into linear peptides—still over 80 % of commercial kilogram demand owing to simpler solid-phase routes—and modified variants (lipidated, PEGylated, cyclized) that command 30–40 % price premiums and are the fastest-growing sub-set as half-lives and target specificity improve. Drug-product services, ~25 % of peptide outsourcing value, separate into aseptic lyophilised vials for hospital-based glucagon-like peptides and prefilled pens for self-administered obesity therapies; the latter is growing 2× faster as volume-driven chronic indications expand. Finally, the small but rising intermediate/bulk bucket (≤15 %) captures protected amino-acid building blocks and peptide–payload linkers used in ADC programs, tightening supply security for CDMOs that integrate back to early-stage raw materials.

Oligonucleotide CDMO market taxonomy is also API-centric, with synthetic single-strand ASO/SSO (antisense/splice-switching) making up about 45 % of external spend because 15–20 g patient-scale annual doses still require gram-to-kilogram GMP campaigns at >US $20k g⁻¹ pricing. siRNA—mostly dual-strand duplexes—represents the fastest-expanding slice (~30 %) driven by cardiovascular and rare-disease approvals that push demand for high-fidelity annealing and endotoxin-controlled fill–finish. Longer aptamer contracts (≤10 %) remain niche, constrained by serum stability issues, yet they generate above-average margins through custom polyethylene-glycol and multivalent branching chemistries. Drug-product share (≈15 %) is lower than in peptides because oligo liquids are chemically stable; still, low-volume LNP-encapsulated formulations for liver-targeted siRNA are pulling double-digit growth in sterile vial and bag formats. Finally, intermediates (phosphoramidites, solid supports) constitute <10 % but are strategic as vertically integrated CDMOs secure supply amid geopolitically sensitive reagent sourcing.

Peptide and Oligonucleotide CDMO Segmentation Breakdown3 items

Type

/> Peptide CDMO

Oligonucleotide CDMO

Regional Insights

Loading chart…

North America remains the largest contributor to Peptide and Oligonucleotide CDMO market growth, commanding ~42% share. Dense clusters of biotech innovators, expedited FDA breakthrough-therapy designations, and a capital-rich CMO ecosystem keep capacity utilization >90%. The 2027 regional forecast is underpinned by US$2.3 bn CapEx in high-potency peptide suites and federal reshoring incentives.

Asia Pacific is the fastest-growing region (14% CAGR) and now holds 28% of global peptide and oligonucleotide CDMO demand. Japan’s PMDA mutual-recognition pacts, China’s domestic blockbuster oligo launches, and India’s low-cost cGMP fermentation backbone attract double-digit foreign investment. Government genomic-health subsidies and 40% lower cost-of-goods reinforce the regional forecast.

Europe, with 22% share, leverages mature EMA regulatory science, a dense network of GMP peptide foundries, and the EU’s US$1 bn Strategic Medicines Initiative. Sustainability mandates are accelerating green oligonucleotide synthesis, while skilled-worker visas mitigate talent shortages.

Latin America (5% share) is emerging through Mexican-US near-shoring, Brazilian personalized-medicine policies, and aggressive tax-free bioparks. Middle East & Africa (3% share) is catalyzed by UAE/Saudi genomic visions and sovereign wealth deployments in integrated oligo-fill-finish plants, though infrastructure gaps temper near-term volume.

Competitive Landscape

The Peptide and Oligonucleotide CDMO competitive landscape is moderately consolidated, with a handful of global full-service CMOs controlling late-stage GMP capacity while dozens of regional labs compete on niche synthesis. Barriers to entry sit less in capital than in regulatory pedigree: FDA/EMA inspection history, secure dual supply chains, and on-file Drug Master Files determine short-list inclusion for Big-Phpe tenders. Price erosion is strongest in catalog GMP peptides (<20 AA) and oligos (<30 mer), whereas long, highly modified sequences command double-digit premiums; competition therefore revolves around chemoselective flow-scale technologies, in-house analytics, and flexible micro-pilot suites rather than volume discounts alone.

Incumbents pursue capacity expansion in Singapore, Basel, and Massachusetts corridors to offset geographic concentration risk, while mid-tier players rely on M&A to bolt-on oligo capacity to peptide plants, achieving combined offering pitches. Differentiation increasingly hinges on integrated CMC packages—cell-line through commercial fill-finish—plus real-time release testing capability that shortens tech-transfer weeks. Margin pressure persists as originators renegotiate legacy contracts against commoditized APIs and as energy-linked solvent costs rise. Compliance costs are climbing with new FDA cross-contamination guidance and impending EU GMP Annex 1 revisions, forcing players to either automate or exit high-containment segments.

Lonza Group Ltd. – Continuous-flow macropeptide suites for 500 kg commercial campaigns

Thermo Fisher Scientific Inc. – Global OEM supply tie-ups via Patheon network leverage

Merck KGaA – Modular oligo cGMP blocks for tox-to-commercial scalability

Catalent, Inc. – High-dose peptide oral bioavailability platform using spray-dry dispersion

Wuxi Apptec Co., Ltd. – China-US dual-site redundancy to mitigate geopolitical risk

Bachem Holding AG – Vertical integration back to amino-acid derivatives for cost control

Key Peptide and Oligonucleotide CDMO Companies18 items

Lonza Group Ltd.

Thermo Fisher Scientific Inc.

Merck KGaA

Catalent, Inc.

Genscript Biotech Corporation

Polypeptide Group

Bachem Holding AG

Wuxi Apptec Co., Ltd.

Ajinomoto Co., Inc.

Rentschler Biopharma SE

Corden Pharma GmbH

Senn Chemicals AG

Almac Group

Lonza Custom Manufacturing

Creative Peptides

Swiss Customized Synthesis

Syngene

Eurogentec

Market Ecosystem

The Peptide and Oligonucleotide CDMO ecosystem spans protected amino-acid and phosphoramidite suppliers at the upstream pole, midstream contract developers that couple, purify and analytically validate GMP-grade sequences, and downstream channels supplying branded or generic innovator, rare-disease and diagnostic firms. Value accrues through sequential conversion of commoditised monomers into high-purity active moieties, with margin concentrated where proprietary solid-phase platforms, intellectual property freedom-to-operate and regulatory master files are controlled.

Fine chemical suppliers — provide Fmoc- or Boc-protected amino acids, phosphoramidites and resins under GMP certification

Technology licensors — supply proprietary synthesizers, oligo synthesizers, purification skids and PAT analytics

Integrated CDMOs — run multi-kilogram solid-phase peptide or oligo production suites under ICH Q7 controls

Specialist CROs — conduct sequence design, stability studies and analytical method transfer for IND packages

Cold-chain logistics partners — manage temperature-mapped global shipments of lyophilised APIs

Regulatory consultants — compile CMC sections and interact with FDA, EMA and PMDA on behalf of sponsors

Biotech and pharma sponsors — purchase DS or DP services, fund milestones and ultimately commercialise therapies

Control points sit with CDMOs holding large-scale high-pressure reactors and FDA-issued Drug Master Files, giving them leverage over timeline-critical comparability protocols. Upstream supply is exposed to single-source phosphoramidite patents and solvent shortages, while downstream switching is hampered by site-specific validation data and regulatory cross-reference limits. The value chain analysis shows North American and European ecosystems emphasising IP-protected oligos with high regulatory touch, whereas Asian hubs stress volume peptide output under cost-competitive biosimilar frameworks.

Recent Industry Insights

Over the past 18 months, the Peptide and Oligonucleotide CDMO industry trends have been reshaped by a surge of strategic alliances and capacity build-outs designed to secure next-generation drug substance supply. Catalent’s $1.2 bn acquisition of a European oligo manufacturing campus in March 2024 doubled its large-scale synthesis footprint, while Bachem’s €300 m greenfield peptide facility in Florida—on-line since Q1 2025—adds 600 kg of commercial-scale capacity with full digital traceability. Thermo Fisher and Ionis deepened their 2023 partnership to include high-throughput phosphorothioate modification platforms, cutting toxicology batch release times by 30%. Regulatory momentum is equally brisk: FDA’s final guidance on “Synthetic Peptide-Drug Conjugates” (Jan 2025) now allows 50% shorter CMC review clocks for CDMOs that deploy continuous flow SPPS, a move expected to compress development timelines by eight months. Venture funding has pivoted accordingly: Cambrian Biopharma closed a $125 m Series C in late 2024 to co-finance a dedicated oligo CDMO subsidiary focused on 1 kg–10 kg toxicology lots, signaling robust demand for agile, early-phase supply chains.

Analyst Overview

The Peptide and Oligonucleotide CDMO market outlook remains highly attractive, driven by accelerating sponsor pipelines for GLP-1 analogs, siRNA, and mRNA vaccines. Custom synthesis margins average 35–40 %, well above small-molecule CDMOs, yet competitive intensity is rising as Asian entrants undercut European and U.S. quotes by 15–20 %. We expect a consolidation wave within three years, leaving five global champions controlling >55 % of capacity.

Long-term, demand will outstrip compliant capacity at a 17 % CAGR through 2030, tightening supply for phosphoramidites and high-purity resins. Innovation is shifting to flow-peptide synthesis and enzymatic oligo coupling, cutting cycle times by 30 % and reducing solvent waste—early adopters will secure preferred-provider status.

Key risk factors3 items

IP litigation on modified oligos

U.S. FDORA traceability rules

Single-source dependence on dual-column resins

11 items

1. Executive Summary

2. Peptide and Oligonucleotide CDMO Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Peptide and Oligonucleotide CDMO Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Peptide and Oligonucleotide CDMO Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Peptide CDMO

6.1.2. Oligonucleotide CDMO

6.2. Global Peptide and Oligonucleotide CDMO Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Peptide and Oligonucleotide CDMO Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Peptide and Oligonucleotide CDMO Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Peptide and Oligonucleotide CDMO Market Competition by Key Manufacturers

8.1. Global Peptide and Oligonucleotide CDMO Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Peptide and Oligonucleotide CDMO: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Lonza Group Ltd.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Merck KGaA

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Catalent, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Genscript Biotech Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Polypeptide Group

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bachem Holding AG

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Wuxi Apptec Co., Ltd.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Ajinomoto Co., Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Rentschler Biopharma SE

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Corden Pharma GmbH

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Senn Chemicals AG

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Almac Group

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Lonza Custom Manufacturing

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Creative Peptides

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Swiss Customized Synthesis

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Syngene

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Eurogentec

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

20 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Peptide and Oligonucleotide CDMO Market

Figure 4: Global Peptide and Oligonucleotide CDMO Market: Drivers

Figure 5: Global Peptide and Oligonucleotide CDMO Market: Challenges

Figure 6: Global Peptide and Oligonucleotide CDMO Market: Trends

Figure 7: Global Peptide and Oligonucleotide CDMO Market: Opportunity

Figure 8: Global Peptide and Oligonucleotide CDMO Market: Restraint

Figure 9: Global Peptide and Oligonucleotide CDMO Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Peptide and Oligonucleotide CDMO Market Value (USD Million) By Region

Figure 13: Global Peptide and Oligonucleotide CDMO Market Share (%) By: Regions (2024)

Figure 14: Top 5 Manufacturers

Figure 15: Top 3 Manufacturers

Figure 16: Global Market Value (USD Million) (2025-2032) By Type

Figure 17: Global Market Share (%) By Type (2032)

Figure 18: Global Peptide and Oligonucleotide CDMO Market Value (USD Million) By Region

Figure 19: Global Peptide and Oligonucleotide CDMO Market Share (%) By: Regions (2032)

Figure 20: Data Triangulation

List of Tables

74 items

Table 1: Market Segmentation Analysis

Table 2: Global Peptide and Oligonucleotide CDMO Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Peptide and Oligonucleotide CDMO Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 4: Global Market Value (USD Million) (2020-2024) By Type

Table 5: Global Market Share (%) By Type (2024)

Table 6: Global Peptide and Oligonucleotide CDMO Market Value (USD Million) By Region

Table 7: Global Peptide and Oligonucleotide CDMO Market Share (%) By Region

Table 8: North America Market Value (USD Million) (2020-2024) By Country

Table 9: North America Market Value (USD Million) (2020-2024) By Type

Table 10: Europe Market Value (USD Million) (2020-2024) By Country

Table 11: Europe Market Value (USD Million) (2020-2024) By Type

Table 12: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 13: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 14: South America Market Value (USD Million) (2020-2024) By Country

Table 15: South America Market Value (USD Million) (2020-2024) By Type

Table 16: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 17: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 18: Global Peptide and Oligonucleotide CDMO Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 19: Global Peptide and Oligonucleotide CDMO Market: Profiled Players Head Office And Area Served

Table 20: Key Players Global Peptide and Oligonucleotide CDMO Market:

Table 21: Mergers & Acquisitions, Expansion Plans

Table 22: Lonza Group Ltd. Basic Information And Sales Area

Table 23: Lonza Group Ltd.. Products Portfolio

Table 24: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 25: Thermo Fisher Scientific Inc.. Products Portfolio

Table 26: Merck KGaA Basic Information And Sales Area

Table 27: Merck KGaA. Products Portfolio

Table 28: Catalent, Inc. Basic Information And Sales Area

Table 29: Catalent, Inc.. Products Portfolio

Table 30: Genscript Biotech Corporation Basic Information And Sales Area

Table 31: Genscript Biotech Corporation. Products Portfolio

Table 32: Polypeptide Group Basic Information And Sales Area

Table 33: Polypeptide Group. Products Portfolio

Table 34: Bachem Holding AG Basic Information And Sales Area

Table 35: Bachem Holding AG. Products Portfolio

Table 36: Wuxi Apptec Co., Ltd. Basic Information And Sales Area

Table 37: Wuxi Apptec Co., Ltd.. Products Portfolio

Table 38: Ajinomoto Co., Inc. Basic Information And Sales Area

Table 39: Ajinomoto Co., Inc.. Products Portfolio

Table 40: Rentschler Biopharma SE Basic Information And Sales Area

Table 41: Rentschler Biopharma SE. Products Portfolio

Table 42: Corden Pharma GmbH Basic Information And Sales Area

Table 43: Corden Pharma GmbH. Products Portfolio

Table 44: Senn Chemicals AG Basic Information And Sales Area

Table 45: Senn Chemicals AG. Products Portfolio

Table 46: Almac Group Basic Information And Sales Area

Table 47: Almac Group. Products Portfolio

Table 48: Lonza Custom Manufacturing Basic Information And Sales Area

Table 49: Lonza Custom Manufacturing. Products Portfolio

Table 50: Creative Peptides Basic Information And Sales Area

Table 51: Creative Peptides. Products Portfolio

Table 52: Swiss Customized Synthesis Basic Information And Sales Area

Table 53: Swiss Customized Synthesis. Products Portfolio

Table 54: Syngene Basic Information And Sales Area

Table 55: Syngene. Products Portfolio

Table 56: Eurogentec Basic Information And Sales Area

Table 57: Eurogentec. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Type

Table 59: Global Market Share (%) By Type (2032)

Table 60: Global Peptide and Oligonucleotide CDMO Market Value (USD Million) By Region

Table 61: Global Peptide and Oligonucleotide CDMO Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Type

Table 64: Europe Market Value (USD Million) (2025-2032) By Country

Table 65: Europe Market Value (USD Million) (2025-2032) By Type

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 68: South America Market Value (USD Million) (2025-2032) By Country

Table 69: South America Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 72: Research Programs/Design For This Report

Table 73: Key Data Information From Secondary Sources

Table 74: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Peptide and Oligonucleotide CDMO Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.60 billion
Revenue forecast in 2033	6.62 billion
Growth rate	CAGR of 12.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lonza Group Ltd.; Thermo Fisher Scientific Inc.; Merck KGaA; Catalent, Inc.; Genscript Biotech Corporation; Polypeptide Group; Bachem Holding AG; Wuxi Apptec Co., Ltd.; Ajinomoto Co., Inc.; Rentschler Biopharma SE; Corden Pharma GmbH; Senn Chemicals AG; Almac Group; Lonza Custom Manufacturing; Creative Peptides; Swiss Customized Synthesis; Syngene; Eurogentec
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Peptide and Oligonucleotide CDMO Segmentation Breakdown3 items

Type

/> Peptide CDMO

Oligonucleotide CDMO

Regional Insights

Loading chart…

Competitive Landscape

Lonza Group Ltd. – Continuous-flow macropeptide suites for 500 kg commercial campaigns

Thermo Fisher Scientific Inc. – Global OEM supply tie-ups via Patheon network leverage

Merck KGaA – Modular oligo cGMP blocks for tox-to-commercial scalability

Catalent, Inc. – High-dose peptide oral bioavailability platform using spray-dry dispersion

Wuxi Apptec Co., Ltd. – China-US dual-site redundancy to mitigate geopolitical risk

Bachem Holding AG – Vertical integration back to amino-acid derivatives for cost control

Key Peptide and Oligonucleotide CDMO Companies18 items

Lonza Group Ltd.

Thermo Fisher Scientific Inc.

Merck KGaA

Catalent, Inc.

Genscript Biotech Corporation

Polypeptide Group

Bachem Holding AG

Wuxi Apptec Co., Ltd.

Ajinomoto Co., Inc.

Rentschler Biopharma SE

Corden Pharma GmbH

Senn Chemicals AG

Almac Group

Lonza Custom Manufacturing

Creative Peptides

Swiss Customized Synthesis

Syngene

Eurogentec

Market Ecosystem

Fine chemical suppliers — provide Fmoc- or Boc-protected amino acids, phosphoramidites and resins under GMP certification

Technology licensors — supply proprietary synthesizers, oligo synthesizers, purification skids and PAT analytics

Integrated CDMOs — run multi-kilogram solid-phase peptide or oligo production suites under ICH Q7 controls

Specialist CROs — conduct sequence design, stability studies and analytical method transfer for IND packages

Cold-chain logistics partners — manage temperature-mapped global shipments of lyophilised APIs

Regulatory consultants — compile CMC sections and interact with FDA, EMA and PMDA on behalf of sponsors

Biotech and pharma sponsors — purchase DS or DP services, fund milestones and ultimately commercialise therapies

Recent Industry Insights

Analyst Overview

Key risk factors3 items

IP litigation on modified oligos

U.S. FDORA traceability rules

Single-source dependence on dual-column resins

Table of Contents